(AOF) – Eli Lilly has filed a complaint with the United States International Trade Commission to block several companies from importing, selling or distributing what they represent as tirzepatide, the active pharmaceutical ingredient (API) of Mounjaro, his medicine against diabetes. The American laboratory emphasizes that neither the FDA nor any other international regulatory body verifies the safety, quality or effectiveness of the products that these companies import or distribute.
In fact, testing shows that at least one of the companies claiming to sell tirzepatide was actually only selling sugar alcohol. Eli Lilly is committed to patient safety and therefore seeks to prevent these companies from exposing patients to potentially serious health risks.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.